Scaling Up the Value

BioLamina

Manufacturing proteins to support turning cells into any organ of the human body may seem like a movie scene, but BioLamina, a flourishing Swedish company makes it seem more real. Dedication, knowledge and the right environment are the necessary tools to achieve the goal of scaling up and growth. With that in mind, the team from BioLamina entered Testa Center.

 

Mission accomplished

The team from BioLamina came out acquiring a new educational level in bioprocessing, do-it-yourself and hands-on experience and increased overall value. One thing they haven’t anticipated is that they will even figure out how to design their own laboratory. They packed their equipment ready to leave, very happy with the outcome of their work at Testa.

We came to Testa center with a 10 Liters scale process already developed to manufacture our product MX/CTG Laminin 521. We aimed to scale up the process to 40 L. Now we have designed a process that allows us to produce and process 40 Liters of harvest multiple times in a month, if necessary”, explains Parinith Sudhakar, an upstream scientist from BioLamina, who spent several months testing and scaling up at the facility.

Testa has passed the test

The future is bright for BioLamina and the next steps for the team is to validate the developed process in house at their own facility, to prepare them for commercial productions.

“The results that we have gotten from Testa makes way to consider scaling the process even further for e.g. to 200 L scale. Besides, we have many more isoforms of Laminins that are in the pipeline; the experience and results add to our strengths to execute our future projects. I don’t exclude the possibility to come back to Testa Center in the future” adds Parinith.

Increasing sales and customer demand had put Biolamina in a situation where production processes needed up-scaling in a quite short time frame. therefore, it has been of paramount importance to be fast and efficient, and Testa has passed the test. Essential, according to BioLamina was the competence from the Testa team. Availability of competence was a key success factor in order to keep the tight timelines. Also, acquainting new skills and getting familiar with new equipment fast, was crucial to them.

“GE is one of the best in bioprocessing business. Learnings from here are great. There were many materials and consumables that we didn’t have knowledge of and the staff at Testa helped us in choosing and ordering the right materials that go into our application beforehand. This saved us a lot of time and we could focus more on the process” adds the scientist.

Upstream and downstream

Testa Center: Can you describe the upstream process at Testa Center?

Parinith Sudhakar In upstream, for one of the unit operation in our scale-up design, we used Ready to Process Wave 25, that we got from Testa center. It was an excellent choice since we could run many small-scale studies to determine optimal operating settings before doing actual scale up. This unit operation simplified our scale-up process.

TC: Was the team from Testa Center helpful?

PS: Even before I did these small-scale studies, I had taken up a few technical discussions with the upstream specialist at Testa center and a GE sales member to evaluate the feasibility of the idea. Also, some suggestions from their experience made us rule out certain types of materials/options which could contribute to poor process design. The discussions were very useful to go ahead with more confidence. This wouldn’t have been possible if we we’re to take these decisions by ourselves.

TC: Did you get help for the downstream process?

Parinith Sudhakar Same thing applies to the downstream process. The downstream specialist at Testa had arranged a meeting between us and other experts from GE campus. This was even before we started to execute our plan. Hearing comments on our ideas from many experts reaffirmed our confidence.

   The equipment

    Testa has provided the essential instrument and consumables:

  • XDM-50 and -100 mixer for loading preparation

  • 3D bags

  • ÄKTA pilot 600

  • BPG100/500 column

 

 

 

 

 

 

 

 

 

 

Testa Center welcomes the SciAR Company to test AR/MR in Bio-process labs

The Finnish company Sciar Company ltd. creates software for Augmented Reality (AR) and Mixed Reality (MR) to take human errors out of the equation in Life Science laboratories. Testa Center, as a bridge between innovation, science and industry, could contribute to the development of their product. SciAR has a primary position twice: as a first company to test digital product in the facility, as well as a first actor outside Sweden to use Testa Center.

The team from SciAR company, founded by three bio-sciences students from University of Helsinki has already visited the Bio-process Innovation Hub, Testa Center in Uppsala several months ago, conveying possibility for future collaboration. Now, they are coming back strong to test their minimum valuable product and two other pilots.

“Lotta Ljungqvist, the CEO of Testa Center, held a presentation at the start-up and tech event “SLUSH” in Helsinki. We were very interested to find out more, so we contacted the responsible person at Testa Center and we decided to visit it and talk about the details”, explains Felix Erkinheimo, one of the co-founders of SciAR.

During the proposed Testa Center project, SciAR would like to verify their technology in an authentic bio-process laboratory setting. They will demonstrate that augmented reality can streamline the workflow and prevent unfortunate errors, as errors can be extremely costly in this type of work. The founders say that there is no facility as unique as Testa Center in Finland, neither in the other Nordic countries, that serves as a bridge between research, innovation and industry.

“We are very impressed. The facility is great, both that it is a cooperation between the industry, the science and the Swedish government and the idea that the Testa Center should be open for innovation. We’re also very impressed how much Microsoft has helped us by lending the HoloLens device for us and helping us with the development.” emphasizes Joel Noutere, CEO and co-founder of SciAR.

SciAR aims to tackle the persisting problems of unstandardized bio-scientific research by eliminating human errors. Combinations of AR- and MR- technologies, are the driving force behind the idea to make the results easier to compare and to take the human errors out of the equation. The software focuses on the person at the laboratory, helping the scientist to get best results, by minimizing the use of reagents and contributing to a better time management. The SciAR company aims to use this technology for fully automated data mining in the future.

Using markers and machine vision and IoT device to recognize the equipment and user actions will make the whole process faster, more reliable and much cheaper. According to the founders, the technology can be used for personalized medicine and faster development of new biopharmaceutical drugs. Their product is about to enter phase one of testing. The company has already developed their minimum viable product and the visit at Testa Center and additionally, two other pilots will tell which features will be developed next!

We have an approach to work together with the potential client to fulfill their need”, finishes Kristian Alaviuhkola, one of the co-founders.

XR in Life Sciences and SciAR company presentation, Kristian Alaviuhkola, 24 May 2019, in Testa Center.

“We are very impressed. The facility is great, both that it is a cooperation between the industry, the science and the Government and the idea that the Testa Center should be open for innovation”, emphasizes Joel Noutere, CEO and co-founder of SciAR.

 

 

GE to sell Biopharma Business to Danaher

In an announcement on February 25, GE announced the proposed sale of parts of the current Life Sciences business to US-based Danaher Corporation. The transaction, is subject to customary closing conditions, including regulatory reviews and appropriate consultation processes, and is expected to be complete by 4Q 2019.

Testa Center, as a non-profit company owned and operated by GE Healthcare in Uppsala, is part of the proposed transaction with Danaher Corporation.

“We continue to serve our customers, stakeholders, and researchers at Testa Center without interruption. Once the transaction is complete, we’ll have a wonderful opportunity to offer even more resources for innovative research”, said Lotta Ljungqvist, CEO Testa Center.

GE Healthcare Life Sciences consists of Biopharma and Pharmaceutical Diagnostics. Pharmaceutical Diagnostics will remain part of the GE Healthcare portfolio. GE Biopharma is a leading provider of instruments, consumables, and software that support the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs. The business comprises process chromatography hardware and consumables, cell culture media, single-use technologies, development instrumentation and consumables, and service.

Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving the quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets.

Danaher’s plans call for the intended acquisition to be run as a standalone operating company.

Otaernam res dus aliquisciis

Please Touch: GE Is Helping America’s Largest Healthcare Provider Bring 3D Printing To Its Hospitals. Occum sus est pratibeatem nonsed eserisciame vit as discimus. Es voloremque quaernam ini veribus earis elicimus sus. Ute pore vellabo rporepe liatem quoditiunt int et aut que earchic.

Otaernam res dus aliquisciis

Please Touch: GE Is Helping America’s Largest Healthcare Provider Bring 3D Printing To Its Hospitals. Occum sus est pratibeatem nonsed eserisciame vit as discimus. Es voloremque quaernam ini veribus earis elicimus sus. Ute pore vellabo rporepe liatem quoditiunt int et aut que earchic.

Otaernam res dus aliquisciis

Please Touch: GE Is Helping America’s Largest Healthcare Provider Bring 3D Printing To Its Hospitals. Occum sus est pratibeatem nonsed eserisciame vit as discimus. Es voloremque quaernam ini veribus earis elicimus sus. Ute pore vellabo rporepe liatem quoditiunt int et aut que earchic.

Otaernam res dus aliquisciis

Please Touch: GE Is Helping America’s Largest Healthcare Provider Bring 3D Printing To Its Hospitals. Occum sus est pratibeatem nonsed eserisciame vit as discimus. Es voloremque quaernam ini veribus earis elicimus sus. Ute pore vellabo rporepe liatem quoditiunt int et aut que earchic.

Otaernam res dus aliquisciis

Please Touch: GE Is Helping America’s Largest Healthcare Provider Bring 3D Printing To Its Hospitals. Occum sus est pratibeatem nonsed eserisciame vit as discimus. Es voloremque quaernam ini veribus earis elicimus sus. Ute pore vellabo rporepe liatem quoditiunt int et aut que earchic.

Uppsala University Master’s Students at Testa Center

The long-term collaboration agreement with Uppsala University and GE Healthcare gives not only researchers, but also students access to the equipment and specialized expertise at Testa Center.

Now in December we are thrilled to have the first class of last-year students on the Master of Science programme in Molecular Biotechnology Engineering at Uppsala University at Testa Center for a student lab exercise. By locating parts of the training at Testa Center the students will gain important experience in industrial processes that cannot be offered in the university’s own laboratories.

Direct feedback from the students confirm the above notions and that the experience in Testa Center has been very inspiring and that they have done important learnings around scaling up (from lab scale to industrial scale). In addition, for many of the students some of the unit operations were completely new, e.g., a filtering step for harvest, which speaks to the importance of bringing in industrial processes in educational programs.

Through the experiences gained at Testa Center the university will also be able to develop completely new programs focusing on large-scale production of biomedicals and bioprocesses. In the longer term this will also contribute to Sweden retaining a leading position in biological processes and the production of biological drugs.

 

 

BioLamina at Testa Center

The Swedish biotechnology company BioLamina was the first actor to run their project at Testa Center. BioLamina was founded in 2008 by Dr. Karl Tryggvason and his son Dr. Kristian Tryggvason, and today the company has grown into a business with global presence and about 20 employees.

BioLamina develops, manufactures and distributes premium cell culture reagents intended for culturing of primary cells, such as stem cells. They recently entered into a collaboration with the pharmaceutical company Novo Nordisk to support the development of new cell therapies targeting Parkinson’s disease, heart failure and loss of vision.

With the aim to scale up their production capacity, BioLamina already early on decided to come to Testa Center which was then made possible through financing support from Swelife. By having access to an extensive array of equipment and the special expertise provided at Testa Center, they have been able to test their own processes and continue building on their own skills and knowledge. Through this competence BioLamina will have the possibility to continue to build their own production capabilities and thereby also keeping it in Sweden.

Kristian Tryggvason, CEO of BioLamina concludes that “With the increasing demand of our high-quality laminins within the cell therapy industry, we need to scale-up our production capacity. Testa Center gives us a unique possibility to do this internally, by securing company assets and know-how, and thereby minimizing business risks.”.

BioLamina press-release

Press release 2018-08-21

GE Healthcare press and news releases

Swedish Government and GE Healthcare Open an Innovation Center for Life Sciences

Turning a stem cell into a brain cell isn’t easy – this company does it every day and finally received the resources to scale

BioLamina and Testa Center in the news

GE Healthcare opens bioprocessing “test bed” for biotechs

Sweden & GE Healthcare Open Testa Center

Sweden,United Kingdom : Swedish Government and GE Healthcare Open an Innovation Center for Life Sciences

A new Swedish innovation center for life sciences is open

Swedish Centre to Support Technologies and Manufacturing

Freedom of innovation: GE opens $17m Swedish biotech testing center

Testcentret för biologiska läkemedel på plats

Biolamina första bolaget till det nya innovationscentret Testa Center

Testbädd för biologiska läkemedel invigd

Testbädd för bioläkemedel invigd

Här får innovationer luft under vingarna